Efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation

BACKGROUND At present,colorectal cancer is routinely treated with adjuvant radiotherapy and chemotherapy postoperatively.The adverse effects(AEs)of chemotherapy usually interrupt the treatment of chemotherapy.Traditional Chinese medicine(TCM)has demonstrated great potential in improving patients'clinical symptoms,regulating the immune function,improving the life quality,and reducing the AEs of chemotherapy.AIM To observe the clinical efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation.METHODS Data from patients diagnosed with colorectal cancer between January 2019 and February 2021 were collected from Liaoning Cancer Hospital and Institute and the Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine.Patients receiving the chemotherapy regimen of capecitabine plus oxaliplatin(CAPOX)after radical resection of colorectal cancer were prospectively collected and randomly divided into an experimental group and a control group.The experimental group was given Yiqi Jianpi anti-cancer prescription combined with the CAPOX regimen,while the control group was given the CAPOX regimen alone.After six cycles of chemotherapy,the scores of TCM symptoms,Karnofsky performance scale(KPS)score,levels of T-cell subsets,and AEs after chemo therapy of the two groups were compared.RESULTS A total of 70 patients were randomly divided into either an experimental group(n=35,no dropout)or a control group(n=33,with 2 dropouts).Compared with the control group,the experimental group improved significantly(P<0.05)in scores of TCM symptoms,KPS score,levels of T-cell subsets,and AEs of chemotherapy.CONCLUSION Yiqi Jianpi anti-cancer prescription can effectively improve spleen deficiency,regulate the immune function,and alleviate the AEs of chemotherapy,so as to improve the life quality of patients with good therapeutic effects and application prospect in clinical practice.

Clinical observation of treatment with Yiqi Jianpi decoction combined with FOLFOX4 for the postoperation patients of colorectal cancer

Objective: The aim of the study was to observe the clinical efficacy with Yiqi Jianpi decoction combination with FOLFOX4 for the postoperative patients of colorectal cancer (CRC). Methods: Eighty-five patients were randomly divided into two groups. The treated group (n = 41) received Yiqi Jianpi decoction combined with FOLFOX4 chemotherapy and the control group (n = 44) received FLOFOX4 chemotherapy alone. A treatment course of 6 months was applied to both groups. Results: The life quality, symptomatic improvement and adverse side effects reducing in the treated group were better than those of the control group. Conclusion: Yiqi Jianpi decoction combination with FOLFOX4 chemotherapy is effective in the treatment of the postoperative patients with colorectal cancer.

Effect of Yiqi Jianpi plus anticancer herbs on spleen deficiency in colorectal cancer and its anti-tumor role

Objective:To observe the effect of Yiqi Jianpi plus anticancer herbs on spleen deficiency in colorectal cancer and its anti-tumor role.Methods:Human intestinal cancer cell HT29 xenograft of nude mice model was established.The expression of ECF,VEGF,gastric cancer tumor growth in mice were observed.Results:Protein kinase C expression in in the Yiqi Jianpi group and Yiqi Jianpi anti-tumor group was significantly better than the model group(P<0.01,P<0.05).There was significantly more apoptotic cells in Yiqi Jianpi anti-tumor group than Yiqi Jianpi group and model group(P<0.01).Epidermal growth factor and vascular endothelial growth factor expression in Yiqi Jianpi group was significantly lower than Yiqi Jianpi group and model group(P<0.05).Conclusions:Tumor can inhibit the expression of PKC inhibition.Yiqi Jianpi and anticancer treatment can reduce this inhibition.Besides this treatment can also inhibit expression of tumor related genes such as epidermal growth factor and vascular endothelial growth factor.

Effect of Yiqi Jianpi Bushen Recipe (益气健脾补肾方) in Reducing Nephrotoxicity of Cisplatin

Objective: To observe the clinical effect of Yiqi Jianpi Bushen recipe (YQJPBS, 益气健脾补肾方) in antagonizing nephrotoxicity and hematological toxicity by cisplatin (CDDP). Methods: The patients with different types of carcinomas were divided into two groups. One group was treated by western medicine (WM), i.e. cisplatin combined with diuretic therapy. The other group by Chinese medicine (CM). One day before chemotherapy, YQJPBS was given orally. Urinary enzyme (NAG, γ-GT, ALP) and serum erythropoietin (Epo) were used as the key monitoring indicator. Results: The early renal damage by CDDP remains near proximal convoluted tubule, which leads to the rising of urinary enzyme. So urinary enzyme of the CM group was obviously lower than that of the WM group. The lesion of renal interstitial cells that produce Epo did not cause the serum Epo of WM group to rise obviously 15 days later. As a result there was 40% patients whose RBC and Hb became lower than the standard count. While serum Epo of CM group was higher than that of WM group, only 5% patients in the CM group had their RBC and Hb lowered. Conclusion: YQJPBS can effectively antagonize nephrotoxicity and hematological toxicity induced by CDDP.

Hemostatic mechanism of the effect of Jianpi Yiqi Shexue decoction on vascular factors in immune thrombocytopenia model mice

Objective: To explore the hemostatic mechanism of Jianpi Yiqi Shexue decoction(JYSD) by regulating vascular factors in an immune thrombocytopenia(ITP) mouse model.Methods: An ITP mouse model was established by the passive-immune modeling method, and interventional drugs used were prednisone tablets and JYSD. The platelet count;vascular activity-related factors v WF, VCAM-1, and TM;and VEGF and b FGF were used as observational indicators.Results: On the 8th day of administration, compared with the model group, platelet counts in the prednisone and JYSD groups increased(both P <.001). Compared with the control group, the levels of v WF, VCAM-1, and TM in the other groups were lower(all P <.05). The VCAM-1 level in the JYSD group was higher than that in the prednisone group(P =.012), but without significant difference compared with the model group(P =.051). The TM level in the JYSD group was the lowest(vs. the model group,P =.047;vs. the prednisone group, P =.006). Compared with the control group, the IOD values of VEGF and b FGF in the other three groups were lower(all P <.01). The IOD values of VEGF in the prednisone and JYSD groups were both higher than those in the model group(P =.002 and P <.001, respectively). The IOD values of b FGF among the model, prednisone, and JYSD groups were not statistically significant(P >.05).Conclusion: A vascular factor disorder is involved in the pathogenesis of ITP. JYSD can increase the platelet count, upregulate VEGF expression, and reduce the TM level. JYSD has the same effect as prednisone tablets in regulating platelet, v WF, VEGF, and b FGF, with a stronger effect in normalizing VCAM-1 and TM levels. The hemostatic mechanism of JYSD is closely related to the effective balance of vascular factors.

益气健脾汤加味联合化疗对结直肠癌术后患者血清细胞因子及胃肠功能的影响

目的:观察益气健脾汤加味联合化疗对结直肠癌术后患者血清细胞因子及胃肠功能的影响。方法:84例结直肠癌患者根据随机数字表法分为治疗组、对照组各42例。2组均给予两孔腹腔镜下根治术治疗,对照组术后给予化疗治疗,治疗组术后给予益气健脾汤加味联合化疗治疗。比较2组治疗前后中医证候评分及血清炎症因子、免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+));比较2组临床疗效、首次排气时间、首次排便时间及不良反应发生率。结果:治疗组总有效率85.71%,高于对照组66.67%(P<0.05)。2组治疗后中医证候评分、外周血CD8^(+)及血清肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6水平均较治疗前降低(P<0.05),外周血CD4^(+)水平及CD4^(+)/CD8^(+)升高(P<0.05),且治疗组中医证候评分、血清炎症因子及外周血CD8^(+)水平低于对照组(P<0.05),外周血CD4^(+)水平及CD4^(+)/CD8^(+)高于对照组(P<0.05)。治疗组首次排气时间、首次排便时间均短于对照组(P<0.05),不良反应发生率低于对照组(P<0.05)。结论:益气健脾汤加味联合化疗治疗能够加快患者胃肠功能恢复,改善炎症状态,提高免疫功能,降低不良反应的发生,临床疗效显著。

健脾益气方对脾虚小鼠胃肠动力、血清淀粉酶、GAS及血浆MTL的影响

目的分析健脾益气方对脾虚小鼠胃肠动力、血清淀粉酶、胃泌素(GAS)及血浆胃动素(MTL)的影响。方法将80只小鼠随机分为空白对照组、模型组、JPYQ-低剂量组、JPYQ-中剂量组、JPYQ-高剂量组,每组16只。除空白对照组外,其余各组均采用大黄水煎液灌胃造小鼠脾虚模型,JPYQ-低剂量组、JPYQ-中剂量组、JPYQ-高剂量组分别给予10.00 g/(kg·d)、20.00 g/(kg·d)、40.00 g/(kg·d)健脾益气方治疗。比较各组的体质量、血清淀粉酶、GAS、血浆MTL水平、脾脏指数、胸腺指数、胃内色素相对残留率及小肠推进率。结果给药后,JPYQ-高剂量组的体质量高于JPYQ-低剂量组、JPYQ-中剂量组(P<0.05)。血清淀粉酶、GAS及血浆MTL水平比较,JPYQ-高剂量组>JPYQ-中剂量组>JPYQ-低剂量组>模型组(P<0.05)。脾脏指数比较,JPYQ-高剂量组>JPYQ-中剂量组>JPYQ-低剂量组>模型组(P<0.05);JPYQ-高剂量组的胸腺指数高于JPYQ-低剂量组、JPYQ-中剂量组及模型组(P<0.05)。胃内色素相对残留率比较,JPYQ-高剂量组<JPYQ-中剂量组JPYQ-低剂量组<模型组(P<0.05);小肠推进率比较,JPYQ-高剂量组>JPYQ-中剂量组>JPYQ-低剂量组>模型组(P<0.05)。结论健脾益气方可明显改善脾虚小鼠胃肠动力、血清淀粉酶、GAS和血浆MTL水平,且高剂量应用的效果更佳。

健脾益气平喘方联合冬病夏治之穴位敷贴对缓解期支气管哮喘(肺气虚证)患者的作用效果

目的 探究健脾益气平喘方联合冬病夏治之穴位敷贴对缓解期支气管哮喘(肺气虚证)患者的作用效果。方法 以随机数字表法将安阳市中医院在2019年3月至2020年3月收治的110例缓解期支气管哮喘(肺气虚证)患者分为两组,接受冬病夏治之穴位敷贴治疗为对照组,接受健脾益气平喘方联合冬病夏治之穴位敷贴治疗为观察组,每组55例,3 a为1个治疗周期。比较两组临床疗效,治疗前后中医证候评分、血液流变学水平、免疫功能[γ干扰素(IFN-γ)、免疫球蛋白(IgE)、白细胞介素(IL)-4]以及抗氧化[超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)]水平。结果 观察组总有效率高于对照组(P<0.05);与治疗前比,治疗后两组中医证候评分均下降,观察组比对照组低(P<0.05);与治疗前比,治疗后两组高切、中切、低切全血黏度均下降,观察组比对照组低(P<0.05);与治疗前比,治疗后两组IL-4、IgE、MDA水平均下降,观察组比对照组低;IFN-γ、SOD、GSH-Px水平上升,观察组比对照组高(P<0.05)。结论 健脾益气平喘方联合冬病夏治之穴位敷贴治疗用于缓解期支气管哮喘(肺气虚证)患者,能够改善患者生活质量,缓解临床症状,改善机体微循环,调节免疫功能,提高机体抗氧化能力。

健脾益气摄血方对免疫性血小板减少症小鼠乏力症状的治疗作用及机制

目的 探讨健脾益气摄血方对免疫性血小板减少症(Immune thrombocytopenia, ITP)小鼠的治疗作用及机制。方法 将90只SPF级BALB/c小鼠按随机数字表法分为正常对照组、模型组、强的松组、健脾益气摄血组(中剂量组、高剂量组),每组18只。正常对照组经腹腔注射生理盐水100μL/20 g,其余各组经腹腔注射抗小鼠血小板血清(APS)100μL/20 g,1次/d,建立ITP小鼠模型。造模第8天开始,正常对照组、模型组给予0.1 mL/10 g生理盐水灌胃,强的松组及健脾益气摄血中、高剂量组均予0.1 mL/10 g相应药物灌胃,1次/d,共给药8 d。Western blotting法检测构成线粒体电子传递链复合物Ⅱ的琥珀酸脱氢酶黄素蛋白亚基A (SDHA)及调控线粒体蛋白质稳态的关键蛋白酶ClpP、LonP1蛋白表达,荧光定量PCR法检测SDHA、ClpP、LonP1 mRNA表达。结果 模型组脾脏、心脏与脑组织SDHA蛋白表达高于正常对照组(P<0.05),强的松组、健脾益气摄血组脾脏SDHA蛋白表达低于模型组(P<0.05);模型组脾脏、心脏和骨骼肌ClpP蛋白表达均高于正常对照组(P<0.05),各治疗组脾脏ClpP表达均低于模型组(P<0.05);模型组脾脏组织LonP1表达低于正常对照组(P<0.05),强的松组脾脏组织LonP1表达高于模型组(P<0.05),而模型组心脏和骨骼肌LonP1表达均高于正常对照组(P<0.05),强的松组骨骼肌LonP1表达低于模型组(P<0.05)。蛋白检测结果与相应组织的mRNA转录水平检测结果基本相符。结论 健脾益气摄血方可调节ITP小鼠线粒体功能,从而改善乏力症状。

益气健脾方对急性酒精肝模型小鼠的防治作用及代谢组学分析

目的 探讨益气健脾方对急性酒精肝的防治作用及代谢组学机制。方法 将30只雄性C57BL/6小鼠分为正常对照组、益气健脾方高剂量对照组、模型组、益气健脾方低剂量组和益气健脾方高剂量组。除对照组外,其余各组采用33%酒精建立急性酒精肝小鼠模型,检测血清中各项生化指标,观察肝组织病理情况。采用液相色谱-质谱联用技术(LC-MS)检测各组小鼠血清代谢物,采用ProgenesisQI、SPSS等进行数据分析,分析各组间的差异代谢物和益气健脾方的可能作用机制。结果 与正常对照组比较,益气健脾方高剂量对照组肝损伤和肝功能无明显变化,模型组丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)、乳酸脱氢酶(LDH)、胆固醇(CHOL)水平升高(P<0.05)。与模型组比较,益气健脾方低、高剂量组ALT、AST、ALP、LDH、CHOL含量降低(P<0.05),肝损伤和肝功能改善。采用LC-MS检测各组小鼠血清代谢物,筛选获得46个差异代谢物,主要涉及的代谢通路包括脂质代谢、氨基酸代谢、类固醇激素生物合成等。结论 益气健脾方能够缓解小鼠急性摄入大量酒精引起的肝损伤和肝功能障碍,益气健脾方对急性酒精肝的保护作用可能与脂质代谢、氨基酸代谢、碳水化合物代谢有关。

健脾益气方干预内质网应激IRE1α-XBP1通路诱导腹膜间皮细胞自噬防治PF的机制

目的 研究健脾益气方通过干预腹膜透析(PD)大鼠内质网应激IRE1α-XBP1通路,诱导自噬以减轻腹膜间皮细胞(PMC)上皮间充质转化(EMT)的作用及机制。方法 SD大鼠72只,采用5/6肾切除联合腹膜透析液制备腹膜纤维化(PF)模型,随机分为假手术组、模型组、西药组、中药高、中、低剂量组,每组12只,进行28 d药物干预。苏木素-伊红(HE)染色观察腹膜组织形态学改变,免疫组化、Western印迹及RT-聚合酶链反应(PCR)测定IRE1α-XBP1通路自噬及纤维化标志蛋白表达。结果 与模型组比较,假手术组、西药组、中药高、中、低剂量组葡萄糖调节蛋白(GRP)78、XBP1s、微管相关蛋白1轻链(LC)3-Ⅱ、自噬相关蛋白Beclin-1、E-钙黏蛋白(cadherin)、α-肌动蛋白(SMA) mRNA及蛋白、pIRE1α蛋白表达差异均有统计学意义(P<0.05)。结论 健脾益气方能够通过干预内质网应激通路IRE1α-XBP1诱导PMC自噬,激活其适应性保护作用,达到减轻PMC的EMT、改善腹膜功能,最终起到拮抗PF作用。

分析小儿单纯性肥胖症应用益气健脾汤治疗的效果

目的 分析小儿单纯性肥胖症应用益气健脾汤治疗的效果。方法 选取78例小儿单纯性肥胖症患儿开展本次研究,随机将其分为对照组(行常规西药治疗, 39例)和观察组(在常规西药治疗的基础上另加益气健脾汤治疗, 39例)。比较两组血脂指标[高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)]及肝功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)]水平,治疗效果。结果观察组的HDL-C(1.53±0.39)mmol/L高于对照组的(1.01±0.15)mmol/L, TG(1.55±0.35)mmol/L、LDL-C(2.40±0.48)mmol/L、TC(4.60±0.35)mmol/L、ALT(30.00±8.61)U/L、AST(27.68±9.11)U/L均低于对照组的(1.99±0.68)mmol/L、(2.99±0.83)mmol/L、(4.99±0.65)mmol/L、(36.14±9.99)U/L、(37.37±9.44)U/L,组间差异明显(P<0.05)。观察组总有效率97.44%高于对照组的82.05%,组间差异明显(P<0.05)。结论 给予小儿单纯性肥胖症患儿益气健脾汤治疗能够显著改善患儿血脂水平和肝功能,临床疗效显著,具有推广价值。

全膝关节置换后服用健脾益气活血方患者肌力及疼痛的变化

背景:全膝关节置换后仍有部分患者存在术肢乏力、疼痛改善不理想的情况,临床发现健脾益气活血方可促进全膝关节置换后康复,但具体疗效仍然有待研究。目的:观察健脾益气活血方对初次单侧全膝关节置换后术肢肌力及疼痛的影响。方法:选择74例行初次单侧全膝关节置换的患者,随机分为试验组及对照组,每组37例。两组患者均采用相同手术方式及假体,对照组术后予常规止痛、抗凝、功能锻炼等治疗;试验组术后在对照组治疗基础上服用健脾益气活血方,持续治疗并随访1个月,统计两组术前、术后肌力(屈伸肌群峰力矩、总功量)、目测类比评分、美国特种外科医院评分的变化。结果与结论:①术后14 d及1个月,试验组的伸肌峰力矩、屈肌峰力距、伸膝总功量、屈膝总功量及美国特种外科医院评分相较于对照组改善更佳(P<0.05);②术后7,14 d及术后1个月试验组的目测类比评分相较于对照组改善更佳(P<0.05);③提示健脾益气活血方可有效提高术肢肌力情况,改善患者术后肢体疼痛,加快患者全膝关节置换后的康复。

健脾益气活血汤治疗糖尿病并骨质疏松的疗效及对25-(OH)D、β-CTX、Pref-1的影响

目的:探讨健脾益气活血汤治疗糖尿病(diabetes mellitus,DM)并骨质疏松(osteporosis,OP)的疗效及对25羟维生素D[25⁃(OH)D]、β-骨胶原交联(β-CTX)、前脂肪因子-1(Pref-1)的影响。方法:选择2021年6月至2022年6月在河北省沧州中西医结合医院治疗的DM合并OP患者206例,应用随机数表法将其分为对照组(常规治疗)及观察组(联合健脾益气活血汤)各103例,对比2组疗效、治疗前后中医证候积分、骨密度(BMD)、血清25-(OH)D、β-CTX、Pref-1水平及不良反应。结果:观察组总有效率高于对照组(P<0.05)。治疗后,2组腰背疼痛、无力/肌肉关节刺痛、口干舌燥积分、β-CTX、Pref-1水平降低(P<0.05),且观察组低于对照组(P<0.05)。2组血清25-(OH)D水平,L 2~4、股骨颈、股骨大转子BMD均升高(P<0.05),且观察组高于对照组(P<0.05)。2组不良反应发生率差异无统计学意义(P>0.05)。结论:健脾益气活血汤治疗DM并OP可有效改善患者症状和血清25-(OH)D、β-CTX、Pref-1水平,调节骨代谢,增加BMD,提高疗效。

益气通络、健脾补肾法联合穴位贴敷治疗慢阻肺稳定期的临床疗效分析

目的:探究益气通络、健脾补肾法联合穴位贴敷治疗慢阻肺(COPD)稳定期的临床疗效。方法:选取我院2022年1月~2023年9月收治的COPD稳定期患者180例。按照照随机数字表法将患者分为穴位贴敷组、中药治疗组和联合治疗组,各60例,穴位贴敷组为西医治疗+穴位贴敷,中药治疗组为西医治疗+益气通络、健脾补肾法,联合治疗组为西医治疗+穴位贴敷+益气通络、健脾补肾法,比较治疗前后中医症候积分、肺功能[肺活量占预计值百分比(FVC%pred)、FEVl/FVC、一氧化碳弥散量占预计值百分比(DLCO%pred)]、炎症指标[白介素(IL)-8、肿瘤坏死因子(TNF)-α、C-反应蛋白(CRP)]、心血管舒缩功能因子[内皮素(ET)、内皮素源(NO)]及生活质量(BODE评分系统)差异。结果:治疗后,三组各中医证候积分、各血清炎症指标与ET水平、mMRC等级及BODE指数均显著降低,且联合治疗组显著低于穴位敷贴组及中药治疗组(P<0.05);治疗后,三组各肺功能指标、血清NO水平、第1秒用力呼气容积占预计值百分比(FEVl%pred)及6WMT均显著升高,且联合治疗组显著高于另两组(P<0.05)。结论:益气通络、健脾补肾法联合穴位贴敷法治疗COPD稳定期患者,能有效改善临床症状,减轻炎性反应,增强肺功能,提高患者预后生活质量。

健脾益气泻浊汤治疗COPD急性加重期的疗效及对中医证候积分、动脉血气以及肺功能的影响

目的:探究健脾益气泻浊汤治疗慢性阻塞性肺疾病(COPD)急性加重期的疗效以及对中医证候积分、动脉血气以及肺功能的影响。方法:选取2020年1月~2022年12月期间,本院收治的COPD患者共计80例,采用随机数表法将上述研究对象划分为观察组(n=40)以及对照组(n=40);对照组患者接受COPD常规方案的治疗,观察组患者在上述治疗方案的基础之上联合使用健脾益气泻浊汤进行治疗;记录两组研究对象接受干预前后中医证候积分(咳嗽咳痰、气促气喘、怠倦乏力)、二氧化碳分压(PaCO_(2))、血氧分压(PaO_(2))、血氧饱和度(SaO_(2))水平、最大呼气第一秒呼出气体容积(FEV1)、最大呼气第一秒呼出气体容积/体积分数(FEV1/FVC)以及6min步行试验距离(6MWT)水平以及两组患者接受治疗后并发症发生率,并进行比较。结果:两组研究对象接受接受相应治疗后,主要临床症状的中医证候积分相比治疗前均出现下降,且观察组低于对照组(P<0.05);两组接受干预后,PaCO_(2)水平相比治疗前出现显著下降,与此同时,PaO_(2)、SaO_(2)水平相比治疗前出现明显提升(P<0.05);研究结果显示,两组研究对象接受治疗后,FEV1、FEV1/FVC以及6MWT水平相比治疗前均出现上升,且观察组高于对照组(P<0.05);另外,两组研究对象接受相应干预后,并发症发生率差异无统计学意义(P>0.05)。结论:健脾益气泻浊汤联合常规治疗方案应用于COPD急性加重期患者能够有效减轻患者临床症状、改善血气指标以及肺功能,且安全性高。

益气健脾方联合蟾酥注射液对晚期胃癌T淋巴细胞亚群平衡及胃肠激素的影响

目的分析益气健脾方联合蟾酥注射液治疗晚期胃癌效果及对患者T淋巴细胞亚群平衡及胃肠激素的影响。方法采取随机数字表法将纳入的85例晚期胃癌患者(2021年3月—2022年12月收治)分为两组,对照组患者(42例)采取化疗治疗,中医方案组(43例)患者化疗治疗基础上结合益气健脾方及蟾酥注射液治疗,指标观察:各组疗效、治疗不良反应、中医证候积分(上腹痛及恶心呕吐、食欲减退、消瘦乏力、呕血黑便等)变化及肿瘤标志物水平变化、炎症因子指标变化及T淋巴细胞亚群指标变化、胃肠激素指标变化、肿瘤生活质量评分标准(Karnofsky performance status, KPS)变化。结果对照组与中医方案组治疗总有效率比较[52.38%(22/42)vs 76.74%(33/43)],P<0.05;中医方案组患者不良反应少于对照组(P<0.05);各组治疗前中医证候积分(上腹痛、恶心呕吐、食欲减退、消瘦乏力、呕血黑便等)、糖类抗原19-9(carbohydrate antigen 19-9,CA19-9)及糖类抗原72-4(carbohydr ateantigen72-4,CA72-4)、癌胚抗原(carcinoembryonic antigen, CEA)等肿瘤标志物水平、白介素-6(interleukin 6,IL-6)、白介素-8(interleukin 8,IL-8)与肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)等炎症因子指标、CD_(4)^(+)T淋巴细胞(cluster of differentiation 4,CD_(4)^(+))、CD_(8)^(+)T淋巴细胞(cluster of differentiation 8,CD_(8)^(+))、CD_(4)^(+)/CD_(8)^(+)等T淋巴细胞亚群指标、胃蛋白酶原Ⅰ(pepsinogenⅠ,PGⅠ)与胃蛋白酶Ⅱ(pepsinogenⅡ,PGⅡ)、胃液素(gastrin, GAS)等胃肠激素、KPS评分等指标比较,均P>0.05;治疗后各组患者中医证候积分(上腹痛、恶心呕吐、食欲减退、消瘦乏力、呕血黑便等)、CA19-9及CA72-4、CEA、IL-6、IL-8及TNF-α水平均降低,中医方案组比对照组更低(P<0.05);对照组患者治疗后CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)指标无显著变化(P>0.05),中医方案组CD_(4)^(+)上升,CD_(8)^(+)下降,CD_(4)^(+)/CD_(8)^(+)指标上升(P<0.05);治疗后各组患者PGⅠ及PGⅡ、GAS水平及KPS评分均上升,中医方案组PGⅠ及PGⅡ、GAS水平及KPS评分均高于对照组(P<0.05)。结论益气健脾方联合蟾酥注射液治疗晚期胃癌有助于提升晚期胃癌治疗效果,改善患者病症,调节T淋巴细胞亚群平衡及胃肠激素,抑制机体炎症反应,提升患者生活质量,减少不良反应,治疗安全可靠。

益气健脾汤结合辅助化疗在结直肠癌术后的应用研究

目的:研究益气健脾汤结合辅助化疗在结直肠癌术后患者中的应用效果。方法:选取2022年8月—2023年8月南昌市第三医院普外科收治的70例择期行手术治疗的结直肠癌患者,按照随机数字表法分为对照组和观察组,各35例。对照组术后采用改良FOLFOX6方案治疗,观察组术后采用改良FOLFOX6方案联合益气健脾汤治疗。比较两组治疗前后中医症状积分、匹兹堡睡眠质量指数(PSQI)、血液学指标[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、血管内皮生长因子(VEGF)]、T细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、欧洲癌症研究与治疗组织生活质量问卷-C30(EORTC QLQ-C30)评分及临床疗效。结果:治疗后观察组中医症候积分均明显低于对照组(P<0.05);治疗后观察组PSQI评分低于对照组(P<0.05);治疗后观察组CEA、CA19-9、VEGF水平均低于对照组(P<0.05);治疗后观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均高于对照组,CD8^(+)低于对照组(P<0.05);观察组总有效率为94.29%,对照组为71.43%,观察组明显高于对照组(P<0.05);治疗后观察组EORTC QLQ-C30评分明显高于对照组(P<0.05)。结论:益气健脾汤结合辅助化疗应用于结直肠癌术后患者能够改善其临床症状,提高睡眠质量,降低肿瘤标志物水平,增加机体免疫功能,且疗效较好,能够提高生活质量。

益气健脾汤治疗初发2型糖尿病合并非酒精性脂肪性肝病患者的临床疗效及其对肠道菌群多样性的影响

目的:观察益气健脾汤对初发2型糖尿病合并非酒精性脂肪性肝病患者的临床疗效及其对肠道菌群多样性的影响。方法:选取符合诊断与纳入标准的脾虚湿困证型初发2型糖尿病并非酒精性脂肪性肝病患者68例,随机分为对照组与观察组,每组各34例。对照组采用吡格列酮二甲双胍片口服治疗,观察组在对照组的基础上给予益气健脾汤口服治疗,两组患者疗程均为12周。分别观察两组患者治疗前后中医证候评分、生化指标(FPG、FINS、HBA1c、AST、ALT、GGT)、胰岛素抵抗指数的变化,并评估其临床疗效。采用16S rRNA高通量测序检测各组患者肠道菌群多样性。结果:治疗后两组患者临床疗效比较,观察组优于对照组(P<0.05)。与对照组相比,观察组患者治疗后FPG、FINS、HBA1c、AST、ALT、GGT及HOMA-IR的水平均明显降低(P<0.05)。与对照组相比,治疗后观察组Simpon指数明显的降低,Ace、Chao1与Shannon的指数明显的升高(P<0.05)。结论:益气健脾汤能改善初发2型糖尿病合并非酒精性脂肪性肝病患者胰岛素抵抗,具有降糖和保肝作用,恢复肠道菌群的多样性是其作用机制之一。

益气健脾通便方联合穴位贴敷疗法治疗慢传输便秘临床观察

目的:观察益气健脾通便方联合穴位贴敷疗法治疗慢传输便秘的临床疗效。方法:选取60例慢传输便秘患者随机分为两组各30例。对照组采用琥珀酸普卢卡必利治疗,治疗组采用益气健脾通便方联合穴位贴敷治疗,观察两组临床疗效、生活质量评分、大肠内标记物排出量、血清一氧化氮(NO)含量和肽类神经递质(SP)水平的变化情况。结果:治疗组临床总有效率为93.33%,优于对照组的83.33%(P<0.05)。治疗后两组患者生活质量自评分较治疗前均降低(P<0.05),且治疗组下降明显(P<0.05);治疗后两组患者48 h和72 h后大肠内标记物排出量均较治疗前相同时间点增加(P<0.05),且治疗组较对照组增加明显(P<0.05);两组患者SP水平均上升(P<0.05),NO含量均降低(P<0.05),且治疗组SP水平、NO含量改善情况均优于对照组(P<0.05)。结论:益气健脾通便方联合穴位贴敷治疗慢传输便秘效果良好。